Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
原发性和转移性中枢神经系统肿瘤的疫苗免疫毒素和放射免疫治疗
基本信息
- 批准号:8508884
- 负责人:
- 金额:$ 305.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-11 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AftercareAlbuminsAlpha ParticlesAnimal ModelAntigensAstatineAstrocytomaAutoimmunityBiostatistics CoreBrainBrain NeoplasmsBreastBreast CarcinomaCathetersCentral Nervous System NeoplasmsCerebrospinal FluidClinicalClinical TrialsCollaborationsComputational algorithmConduct Clinical TrialsControl GroupsConvectionCytomegalovirusDiscipline of Nuclear MedicineDoseEligibility DeterminationEpidermal Growth Factor ReceptorExotoxinsExternal Beam Radiation TherapyGadolinium DTPAGlioblastomaHematopoieticImageImmune responseImmunologic MonitoringImmunologicsImmunosuppressionImmunosuppressive AgentsImmunotherapyImmunotoxinsInformaticsIntrathecal ChemotherapyLabelLong-Term SurvivorsLungLymphopeniaMalignant - descriptorMalignant NeoplasmsMetastatic Neoplasm to the LeptomeningesMethodologyMethodsModelingMonitorMonoclonal AntibodiesMusNewly DiagnosedPathway interactionsPatientsPerformancePhasePhase I Clinical TrialsPhase II Clinical TrialsPhysiciansPositron-Emission TomographyPrimary Brain NeoplasmsPseudomonasRadiationRadiation therapyRadioactivityRadioimmunotherapyRadioisotopesRadiometryRandomizedRecording of previous eventsRecoveryRecurrenceRefractoryRegulatory T-LymphocyteSafetyScientistSenior ScientistT-LymphocyteTargeted RadiotherapyTissue BankingTissue BanksToxic effectTrastuzumabTumor ImmunityTumor TissueVaccinatedVaccinationVaccinesVertebral columnarmbevacizumabbiobankclinical trials in animalscytotoxicdehalogenationdesigneffective therapyimprovedlung Carcinomameetingsneoplastic cellneuro-oncologynovelnovel strategiesoutcome forecastoverexpressionpanitumumabreceptorstandard of carestatisticstemozolomidetumor
项目摘要
DESCRIPTION (provided by applicant): This is an application to the NCI from a group of senior scientists and physician/scientists with a long history of collaboration who proposes novel approaches for treatment of two of the conditions in neuro-oncology which are most refractory to treatment, neoplastic meningitis (NM) and glioblastoma multiforme (GBM). NM is characterized by the dissemination of malignant tumor cells within the leptomeningeal space and metastatic spread through the cerebrospinal fluid along the brain and spine. NM from carcinoma of the breast and lung are the most common subtypes. Prognosis of NM is grim with median survival of 2 to 6 months. Current therapy is ineffective and limited by toxicity to the CNS. GBM is the most common and most malignant primary brain tumor. Despite hundreds of clinical trials, only two agents, temozolomide and bevacizumab, have been approved for treatment by the FDA in the last decade. Less than half of patients treated with these two agents respond. Recurrence after treatment is almost universal and median survival is 15 to 18 months with few long-term survivors. Targeted immunotherapy with monoclonal antibodies (MAbs) or their fragments armed with Astatine 211 or Pseudomonas exotoxin for the treatment of NM or GBM is proposed in Projects 1 and 3. In Project 2 vaccine approaches against the ubiquitous antigens from CMV in GBM are proposed to be improved by decreasing immunosuppressive regulatory T-cells or TReg in the setting of temozolomide-induced lymphopenia by administering a specific humanized MAb reactive with the IL-2Ra receptor. Project 1, led by Michael Zaiutsky, is entitled "Targeted Radiotherapy of Neoplastic Meningitis using Monoclonal Antibodies Labeled with Alpha Particle Emitting At." Project 2, led by John Sampson, and is entitled, "Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy." Project 3, led by Darell Bigner, and is entitled, "EGFRwt and EGFRvlll Dual-Specific Immunotoxin for Glioblastoma Multiforme." These three projects will be supported by an Imaging Core, Daniel Barboriak, Core Director; a Clinical Support Core for biostatistics, informatics, immune monitoring, and a brain tumor tissue biorepository, James Vredenburgh, Core Director; and an Administrative Core, Darell Bigner, Core Director.
描述(由申请人提供):这是一组资深科学家和医师/科学家向NCI提出的一份申请,他们具有长期合作的历史,他们提出了治疗神经肿瘤学中最难治疗的两种疾病的新方法,肿瘤性脑膜炎(NM)和多形性胶质母细胞瘤(GBM)。NM的特征是恶性肿瘤细胞在脑脊膜间隙内播散,并沿脑和脊柱通过脑脊液转移扩散。来自乳腺癌和肺癌的NM是最常见的亚型。恶性肿瘤预后严峻,中位生存期为2 ~ 6个月。目前的治疗是无效的,而且对中枢神经系统的毒性有限。GBM是最常见、最恶性的原发性脑肿瘤。尽管进行了数百次临床试验,但在过去十年中,只有替莫唑胺和贝伐单抗两种药物被FDA批准用于治疗。在接受这两种药物治疗的患者中,只有不到一半的人有反应。治疗后复发几乎是普遍的,中位生存期为15至18个月,很少有长期幸存者。项目1和项目3提出了用单克隆抗体(mab)或其片段武装Astatine 211或假单胞菌外毒素用于治疗NM或GBM的靶向免疫治疗。在项目2中,针对CMV在GBM中普遍存在的抗原的疫苗方法被提出,通过使用与IL-2Ra受体反应的特异性人源单抗,在替莫唑胺诱导淋巴细胞减少的情况下,通过降低免疫抑制性调节性t细胞或TReg,来改善疫苗方法。项目1由Michael Zaiutsky领导,名为“使用α粒子发射At标记的单克隆抗体靶向治疗肿瘤性脑膜炎”。项目2由John Sampson领导,名为“靶向免疫抑制途径以增强脑肿瘤免疫治疗”。项目3由Darell Bigner领导,名为“多形性胶质母细胞瘤的EGFRwt和egfrll双特异性免疫毒素”。这三个项目将由Imaging Core, Core主任Daniel Barboriak;生物统计学、信息学、免疫监测和脑肿瘤组织生物库的临床支持核心,核心主任James Vredenburgh;行政核心,Darell Bigner,核心董事。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DARELL D BIGNER其他文献
DARELL D BIGNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DARELL D BIGNER', 18)}}的其他基金
Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma
项目3:溶瘤脊髓灰质炎病毒(PVSRIPO)联合CCNU(洛莫司汀)治疗复发性胶质母细胞瘤二期试验
- 批准号:
10477340 - 财政年份:2018
- 资助金额:
$ 305.49万 - 项目类别:
Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma
项目3:溶瘤脊髓灰质炎病毒(PVSRIPO)联合CCNU(洛莫司汀)治疗复发性胶质母细胞瘤二期试验
- 批准号:
10006179 - 财政年份:2018
- 资助金额:
$ 305.49万 - 项目类别:
Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma
项目3:溶瘤脊髓灰质炎病毒(PVSRIPO)联合CCNU(洛莫司汀)治疗复发性胶质母细胞瘤二期试验
- 批准号:
10246887 - 财政年份:2018
- 资助金额:
$ 305.49万 - 项目类别:
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
胶质瘤的溶瘤脊髓灰质炎病毒、免疫毒素和检查点抑制剂治疗
- 批准号:
10004580 - 财政年份:2015
- 资助金额:
$ 305.49万 - 项目类别:
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
胶质瘤的溶瘤脊髓灰质炎病毒、免疫毒素和检查点抑制剂治疗
- 批准号:
10221622 - 财政年份:2015
- 资助金额:
$ 305.49万 - 项目类别:
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
胶质瘤的溶瘤脊髓灰质炎病毒、免疫毒素和检查点抑制剂治疗
- 批准号:
9751789 - 财政年份:2015
- 资助金额:
$ 305.49万 - 项目类别:
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
原发性和转移性中枢神经系统肿瘤的疫苗免疫毒素和放射免疫治疗
- 批准号:
8216088 - 财政年份:2012
- 资助金额:
$ 305.49万 - 项目类别:
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
原发性和转移性中枢神经系统肿瘤的疫苗免疫毒素和放射免疫治疗
- 批准号:
8724198 - 财政年份:2012
- 资助金额:
$ 305.49万 - 项目类别:
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
原发性和转移性中枢神经系统肿瘤的疫苗免疫毒素和放射免疫治疗
- 批准号:
8917131 - 财政年份:2012
- 资助金额:
$ 305.49万 - 项目类别:
相似海外基金
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10685312 - 财政年份:2021
- 资助金额:
$ 305.49万 - 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10490872 - 财政年份:2021
- 资助金额:
$ 305.49万 - 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
- 批准号:
10345963 - 财政年份:2021
- 资助金额:
$ 305.49万 - 项目类别:
Development of Highly Functionalized Serum Albumins as Boron Delivery Carries to Tumor for Neutron Capture Therapy
开发高功能化血清白蛋白作为硼输送至肿瘤以进行中子捕获治疗
- 批准号:
17H02202 - 财政年份:2017
- 资助金额:
$ 305.49万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Studies on Asymmetric Nitroaldol Reaction using mutant albumins
突变体白蛋白不对称硝醛醇反应的研究
- 批准号:
16K05706 - 财政年份:2016
- 资助金额:
$ 305.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
SPIN LABELING STUDIES OF NORMAL RECOMBINANT & MUTANT HUMAN SERUM ALBUMINS
正常重组的旋转标记研究
- 批准号:
6118869 - 财政年份:1999
- 资助金额:
$ 305.49万 - 项目类别:
COPPER BINDING OF COMMERCIAL, NORMAL RECOMBINANT, & MUTANT HUMAN SERUM ALBUMINS
商业、正常重组的铜结合,
- 批准号:
6118864 - 财政年份:1999
- 资助金额:
$ 305.49万 - 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia in Fowl
家禽双清蛋白血症血清白蛋白的结构与代谢特征
- 批准号:
67B6472 - 财政年份:1967
- 资助金额:
$ 305.49万 - 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia
双清蛋白血症血清白蛋白的结构和代谢特征
- 批准号:
65B3344 - 财政年份:1965
- 资助金额:
$ 305.49万 - 项目类别: